STOP-HER2: Stopping Trastuzumab in HER2+ MBC
Public ClinicalTrials.gov record NCT05721248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients With HER2+ Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment. Exceptional response" is considered as cancer progression being controlled for three years or more since starting anti-HER2 treatment.
Study identification
- NCT ID
- NCT05721248
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 82 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 18, 2023
- Primary completion
- Jun 21, 2026
- Completion
- May 31, 2036
- Last update posted
- Aug 5, 2026
2023 – 2036
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Hospital Arizona | Phoenix | Arizona | 85054 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 02809 | — |
| Mayo Clinical Hospital Florida | Jacksonville | Florida | 32224 | — |
| Dana-Farber Cancer Insitute | Boston | Massachusetts | 02215 | — |
| DFCI @ Foxborough | Foxborough | Massachusetts | 02035 | — |
| DFCI @ Merrimack Valley | Methuen | Massachusetts | 01844 | — |
| DFCI @ Milford Regional Hospital | Milford | Massachusetts | 01757 | — |
| DFCI @ South Shore Hospital | South Weymouth | Massachusetts | 02190 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05721248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 5, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05721248 live on ClinicalTrials.gov.